Dr. Renu Razdan of Max Neeman International Speaks at Lilly Women India Network Event

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2013 /PRNewswire/ -- Max Neeman International announced today that Chief Operating Officer, Dr. Renu Razdan was a guest speaker at the Lilly Women Network event in India, October 10^th. Dr. Razdan shared her success story as an upper-level executive of the leading Indian CRO;  her journey through leadership, the challenges faced as a woman and the skills she honed to overcome those challenges.

Lilly Women India Network is a platform for women employees to interact, exchange ideas, educate and empower each other to enhance lives and foster professional success.

"Max Neeman and Eli Lilly [India] have shared a positive working relationship for years and I am honored to speak with their female employees regarding my own personal journey to success. Max Neeman's corporate culture has encouraged, valued and acknowledged my hard work and efforts, allowing me to become the COO I am today," said Dr. Razdan.

Dr. Razdan joined the company in 2005 and is responsible for oversight of Operations Departments as well as heading the Business Development team in India for client relations in Europe and South East Asia. She brings over ten years of experience and has played an active role in the development and growth of the company. Prior to joining Max Neeman International, Dr. Razdan worked at Ranbaxy Laboratories Limited for six years, pursued ICRETT Fellowship of UICC Geneva, an international agency for research on cancer, Lyon (France), and G.S.F. Fellowship at German Cancer Research Centre (DKFZ), Heidelberg (Germany).

About Max Neeman International
'Max Neeman' is a leading Asia-Pacific CRO with India expertise and expanded capabilities into N. America and Europe. Since 2001, the company has provided clinical research services for the successful conduct of drug and device trials in compliance with ICH GCP standards. The company is ISO 9001:2008 certified for monitoring, site management and data management with over >400 employees, 245 active sites in various therapeutic areas and 310 trials awarded. Data Management services alone have touched 60 countries.  For more information contact Donald Swankie, Vice President USA: 919-424-3345 donald.swankie@neeman-medical.com or go to www.neeman-medical.com.

SOURCE Max Neeman International